CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Harpoon Therapeutics, Inc. - HARP CFD

8.8980
10.55%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.0640
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026207 %
Charges from full value of position ($-4.98)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026207%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003985 %
Charges from full value of position ($0.76)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003985%
Overnight fee time 22:00 (UTC)
Min traded quantity 0.1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Harpoon Therapeutics Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 9.948
Open* 9.798
1-Year Change* 1301.72%
Day's Range* 8.788 - 9.918
52 wk Range 3.11-33.55
Average Volume (10 days) 181.91K
Average Volume (3 months) 3.13M
Market Cap 219.95M
P/E Ratio -100.00K
Shares Outstanding 16.93M
Revenue 37.34M
EPS -8.71
Dividend (Yield %) N/A
Beta 2.26
Next Earnings Date Mar 25, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Dec 8, 2023 8.8980 -1.1000 -11.00% 9.9980 9.9980 8.7880
Dec 7, 2023 9.9480 -0.0500 -0.50% 9.9980 10.4480 9.7980
Dec 6, 2023 9.9280 -0.6700 -6.32% 10.5980 11.3980 9.4980
Dec 5, 2023 10.5080 0.5100 5.10% 9.9980 10.8080 9.6880
Dec 4, 2023 10.2380 -0.3400 -3.21% 10.5780 11.3280 10.1280
Dec 1, 2023 10.9880 0.8200 8.06% 10.1680 11.1180 10.0980
Nov 30, 2023 10.5980 0.1000 0.95% 10.4980 11.1980 10.0980
Nov 29, 2023 10.3080 0.1100 1.08% 10.1980 10.3880 9.5880
Nov 28, 2023 10.4580 1.0000 10.57% 9.4580 10.5480 9.4580
Nov 27, 2023 9.6480 -2.1000 -17.88% 11.7480 11.9980 8.6480
Nov 24, 2023 11.6780 -0.5200 -4.26% 12.1980 12.6080 11.6780
Nov 22, 2023 12.8380 -0.1600 -1.23% 12.9980 14.9780 11.4080
Nov 21, 2023 12.9380 0.6400 5.20% 12.2980 13.5180 12.0280
Nov 20, 2023 12.8080 1.4000 12.27% 11.4080 13.6880 11.4080
Nov 17, 2023 11.4080 1.8500 19.36% 9.5580 11.4480 9.4480
Nov 16, 2023 9.4180 0.9100 10.70% 8.5080 9.4980 8.4080
Nov 15, 2023 8.6780 0.2800 3.33% 8.3980 9.2380 8.2880
Nov 14, 2023 8.6480 0.8500 10.90% 7.7980 8.7680 7.5480
Nov 13, 2023 7.3080 0.8800 13.69% 6.4280 7.5680 5.9980
Nov 10, 2023 6.3280 0.0600 0.96% 6.2680 6.7280 5.9880

Harpoon Therapeutics, Inc. Events

Time (UTC) Country Event
Monday, March 25, 2024

Time (UTC)

10:59

Country

US

Event

Q4 2023 Harpoon Therapeutics Inc Earnings Release
Q4 2023 Harpoon Therapeutics Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 31.915 23.654 17.444 5.777 4.75
Revenue 31.915 23.654 17.444 5.777 4.75
Total Operating Expense 100.24 140.405 68.775 63.983 32.474
Selling/General/Admin. Expenses, Total 18.847 18.327 16.21 22.391 6.106
Research & Development 81.393 72.124 52.565 41.592 26.368
Operating Income -68.325 -116.751 -51.331 -58.206 -27.724
Interest Income (Expense), Net Non-Operating 0.776 0.24 1.449 2.676 0.395
Other, Net -0.182 -0.21 -0.026 -0.042 -0.037
Net Income Before Taxes -67.731 -116.721 -49.908 -55.572 -27.366
Net Income After Taxes -67.731 -116.721 -49.908 -55.572 -27.366
Net Income Before Extra. Items -67.731 -116.721 -49.908 -55.572 -27.366
Net Income -67.731 -116.721 -49.908 -55.572 -27.366
Income Available to Common Excl. Extra. Items -67.731 -116.721 -49.908 -55.572 -27.366
Income Available to Common Incl. Extra. Items -67.731 -116.721 -49.908 -55.572 -27.366
Diluted Net Income -67.731 -116.721 -49.908 -55.572 -27.366
Diluted Weighted Average Shares 3.31674 3.22744 2.50349 2.17465 2.3909
Diluted EPS Excluding Extraordinary Items -20.4209 -36.1652 -19.9353 -25.5545 -11.4459
Dividends per Share - Common Stock Primary Issue
Diluted Normalized EPS -20.4209 -20.6873 -19.9353 -25.5545 -11.4459
Total Extraordinary Items 0 0
Unusual Expense (Income) 0 49.954
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 20.221 8.583 4.089 13.617 8.303
Revenue 20.221 8.583 4.089 13.617 8.303
Total Operating Expense 15.999 19.348 22.801 25.506 25.714
Selling/General/Admin. Expenses, Total 3.803 4.185 3.854 4.529 5.063
Research & Development 12.196 15.163 18.947 20.977 20.651
Unusual Expense (Income) 0 0 0
Operating Income 4.222 -10.765 -18.712 -11.889 -17.411
Interest Income (Expense), Net Non-Operating -0.945 0.287 0.343 0.289 0.104
Other, Net -2.217 -0.86 -0.05 -0.04 -0.044
Net Income Before Taxes 1.06 -11.338 -18.419 -11.64 -17.351
Net Income After Taxes 1.06 -11.338 -18.419 -11.64 -17.351
Net Income Before Extra. Items 1.06 -11.338 -18.419 -11.64 -17.351
Net Income 1.06 -11.338 -18.419 -11.64 -17.351
Income Available to Common Excl. Extra. Items 1.061 -11.338 -18.419 -11.64 -17.351
Income Available to Common Incl. Extra. Items 1.061 -11.338 -18.419 -11.64 -17.351
Diluted Net Income 1.061 -11.338 -18.419 -11.64 -17.351
Diluted Weighted Average Shares 3.7973 3.69682 3.3689 3.30621 3.30369
Diluted EPS Excluding Extraordinary Items 0.27941 -3.06696 -5.46736 -3.52064 -5.25201
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS 0.27941 -3.06696 -5.46736 -3.52064 -5.25201
Total Adjustments to Net Income 0.001
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 54.727 137.695 129.754 150.617 90.223
Cash and Short Term Investments 53.112 135.098 126.03 148.073 89.493
Cash & Equivalents 51.614 44.687 21.17 88.736 89.493
Total Receivables, Net
Prepaid Expenses 1.615 2.597 3.724 2.544 0.73
Total Assets 73.729 155.452 171.592 176.604 102.58
Property/Plant/Equipment, Total - Net 18.091 15.375 16.771 18.398 8.782
Property/Plant/Equipment, Total - Gross 26.634 21.561 20.767 20.312 4.012
Accumulated Depreciation, Total -8.543 -6.186 -3.996 -1.914 -1.014
Other Long Term Assets, Total 0.911 0.86 1.121 0.533 3.575
Total Current Liabilities 52.433 59.139 47.918 22.513 11.948
Accounts Payable 4.712 2.666 1.572 2.594 4.357
Accrued Expenses 16.784 19.011 15.047 8.712 3.341
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 30.937 37.462 31.299 11.207 4.25
Total Liabilities 68.33 97.382 117.753 82.384 26.482
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 15.897 38.243 69.835 59.871 14.534
Total Equity 5.399 58.07 53.839 94.22 76.098
Redeemable Preferred Stock 0
Common Stock 0.004 0.004 0.003 0.003 0.001
Additional Paid-In Capital 357.921 342.905 221.904 212.339 9.111
Retained Earnings (Accumulated Deficit) -352.523 -284.792 -168.071 -118.163 -62.591
Other Equity, Total -0.003 -0.047 0.003 0.041 0
Total Liabilities & Shareholders’ Equity 73.729 155.452 171.592 176.604 102.58
Total Common Shares Outstanding 3.57867 3.27658 2.55532 2.49048 2.3909
Preferred Stock - Non Redeemable, Net 129.577
Short Term Investments 1.498 90.411 104.86 59.337
Long Term Investments 0 1.522 23.946 7.056
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 34.296 49.067 63.861 54.727 69.149
Cash and Short Term Investments 31.608 45.555 61.385 53.112 66.098
Cash & Equivalents 17.738 32.797 61.385 51.614 50.368
Short Term Investments 13.87 12.758 0 1.498 15.73
Prepaid Expenses 2.688 3.512 2.476 1.615 3.051
Total Assets 47.578 63.199 80.809 73.729 83.496
Property/Plant/Equipment, Total - Net 12.384 12.967 16.168 18.091 13.536
Property/Plant/Equipment, Total - Gross 12.711 13.058 23.495 26.634 21.399
Accumulated Depreciation, Total -0.327 -0.091 -7.327 -8.543 -7.863
Long Term Investments 0 0
Other Long Term Assets, Total 0.898 1.165 0.78 0.911 0.811
Total Current Liabilities 18.106 25.334 44.173 52.433 54.061
Accounts Payable 3.435 3.627 4.002 4.712 2.64
Accrued Expenses 14.671 17.259 17.816 16.784 17.458
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 0 4.448 22.355 30.937 33.963
Total Liabilities 43.037 60.201 80.094 68.33 66.584
Total Long Term Debt 8.827 6.781 5.246 0 0
Other Liabilities, Total 16.104 28.086 30.675 15.897 12.523
Total Equity 4.541 2.998 0.715 5.399 16.912
Common Stock 0.001 0.004 0.004 0.004 0.004
Additional Paid-In Capital 369.141 365.79 364.572 357.921 351.04
Retained Earnings (Accumulated Deficit) -364.602 -362.801 -363.861 -352.523 -334.104
Other Equity, Total 0.001 0.005 0 -0.003 -0.028
Total Liabilities & Shareholders’ Equity 47.578 63.199 80.809 73.729 83.496
Total Common Shares Outstanding 4.10877 3.79726 3.75957 3.57867 3.32287
Long Term Debt 8.827 6.781 5.246
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -67.731 -116.721 -49.908 -55.572 -27.366
Cash From Operating Activities -89.182 -122.154 -8.616 -2.891 -27.126
Cash From Operating Activities 2.357 2.19 2.082 0.9 0.644
Non-Cash Items 9.77 12.287 5.783 2.732 0.672
Changes in Working Capital -33.578 -19.91 33.427 49.049 -1.076
Cash From Investing Activities 89.737 34.354 -63.626 -69.315 -0.663
Capital Expenditures -0.347 -0.1 -0.683 -3.516 -0.663
Other Investing Cash Flow Items, Total 90.084 34.454 -62.943 -65.799 0
Cash From Financing Activities 6.372 111.523 4.676 71.449 88.326
Issuance (Retirement) of Stock, Net 6.372 111.523 4.676 71.449 89.986
Issuance (Retirement) of Debt, Net 0 0
Net Change in Cash 6.927 23.723 -67.566 -0.757 60.537
Financing Cash Flow Items -1.66
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -11.338 -67.731 -49.312 -37.672 -20.321
Cash From Operating Activities -19.286 -89.182 -70.792 -46.841 -25.238
Cash From Operating Activities 0.662 2.357 1.679 1.152 0.604
Non-Cash Items 1.598 9.77 8.064 6.139 3.308
Changes in Working Capital -10.208 -33.578 -31.223 -16.46 -8.829
Cash From Investing Activities 2.438 89.737 75.49 69.84 30.459
Capital Expenditures -0.347 -0.319 -0.053
Other Investing Cash Flow Items, Total 2.438 90.084 75.809 69.893 30.459
Cash From Financing Activities 26.619 6.372 0.983 0.882 0.83
Issuance (Retirement) of Stock, Net 1.619 6.372 0.983 0.882 0.83
Net Change in Cash 9.771 6.927 5.681 23.881 6.051
Financing Cash Flow Items
Issuance (Retirement) of Debt, Net 25
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
Hunt (Ronald M) Individual Investor 1.9155 322399 3035 2023-10-01 HIGH
BioImpact Capital LLC Investment Advisor/Hedge Fund 1.8993 319671 0 2023-06-30 MED
New Leaf Venture Partners LLC Venture Capital 1.8755 315670 0 2023-06-30 LOW
MPM Capital Inc. Investment Advisor/Hedge Fund 1.8605 313139 0 2023-06-30 LOW
Arix Bioscience Investments Limited Venture Capital 1.3017 219092 0 2023-03-23
Franklin Advisers, Inc. Investment Advisor/Hedge Fund 0.7862 132329 0 2023-06-30 LOW
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 0.6851 115315 0 2023-06-30 LOW
Invus Public Equities Advisors, LLC Investment Advisor 0.5941 100000 0 2023-06-30 MED
OrbiMed Advisors, LLC Investment Advisor/Hedge Fund 0.3691 62122 0 2023-06-30 LOW
Cormorant Asset Management, LP Hedge Fund 0.3212 54060 0 2023-06-30 LOW
Kennedy Capital Management, Inc. Investment Advisor 0.3148 52993 0 2023-06-30 MED
Lion Point Capital, L.P. Hedge Fund 0.2712 45651 28723 2023-06-30 HIGH
BlackRock Institutional Trust Company, N.A. Investment Advisor 0.2026 34106 -4965 2023-06-30 LOW
Tekla Capital Management LLC Investment Advisor 0.1544 25991 0 2023-06-30 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 0.1286 21643 0 2023-06-30 LOW
Renaissance Technologies LLC Hedge Fund 0.1269 21360 1718 2023-06-30 HIGH
Millennium Management LLC Hedge Fund 0.0987 16620 -48662 2023-06-30 HIGH
Myers (Scott Dunseth) Individual Investor 0.0928 15618 5797 2023-10-01
Erbez (Georgia L) Individual Investor 0.0583 9821 0 2023-04-05
Telemetry Investments, L.L.C. Hedge Fund 0.0553 9300 9300 2022-12-31 HIGH

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Harpoon Therapeutics, Inc. Company profile

About Harpoon Therapeutics Inc

Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company. The Company is engaged in the development of a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. The Company is engaged in developing pipeline of novel T cell engagers using TriTACs, focused on the treatment of solid tumors and hematologic malignancies. It has also nominated its clinical candidate using ProTriTAC platform, a prodrug version of TriTAC platform, designed to expand the target space for T cell engagers and bring the benefits of TriTACs to the patients. The Company’s four TriTAC product candidates include HPN424, HPN536, HPN217 and HPN328. The Company ProTriTAC product candidate include HPN601.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Harpoon Therapeutics Inc revenues increased 36% to $23.7M. Net loss increased from $49.9M to $116.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development - Balancing increase of 33% to $67.3M (expense), Stock-based Compensation in R&D increase from $2M to $4.8M (expense).

Industry: Bio Therapeutic Drugs

611 Gateway Boulevard, Suite 400
SOUTH SAN FRANCISCO
CALIFORNIA 94080
US

Income Statement

  • Annual
  • Quarterly

News

December RBA preview: no move expected at the final meeting of 2023

The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.

14:47, 4 December 2023

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

12:39, 30 November 2023

Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

EZ PI expected to drop further but speed of decline

08:16, 29 November 2023

A weaker Dollar drives gold higher

Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

13:49, 28 November 2023

Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

13:20, 28 November 2023

RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

13:04, 28 November 2023

Crude prices slide on OPEC+ uncertainty

Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

12:55, 28 November 2023

People also watch

BTC/USD

42,278.50 Price
-3.620% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 106.00

US100

16,050.30 Price
-0.140% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 1.8

XRP/USD

0.63 Price
-6.240% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.01168

Gold

1,996.35 Price
-0.420% 1D Chg, %
Long position overnight fee -0.0199%
Short position overnight fee 0.0117%
Overnight fee time 22:00 (UTC)
Spread 0.50

Still looking for a broker you can trust?

Join the 570.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading